...
首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >Antipsychotic response in first-episode schizophrenia: Efficacy of high doses and switching
【24h】

Antipsychotic response in first-episode schizophrenia: Efficacy of high doses and switching

机译:首发精神分裂症的抗精神病药物反应:大剂量和切换的疗效

获取原文
获取原文并翻译 | 示例

摘要

Clinicians treating schizophrenia routinely employ high doses and/or antipsychotic switching to achieve response. However, little is actually known regarding the value of these interventions in early schizophrenia. Data were gathered from a treatment algorithm implemented in patients with first-episode schizophrenia that employs two antipsychotic trials at increasing doses before clozapine. Patients were initially treated with either olanzapine or risperidone across three dose ranges, (low, full, high), and in the case of suboptimal response were switched to the alternate antipsychotic. We were interested in the value of (a) high dose treatment and (b) antipsychotic switching. A total of 244 patients were evaluated, with 74.5% (184/244) responsive to Trial 1, and only 16.7% (10/60) responsive to Trial 2. Percentage of response for subjects switched from olanzapine to risperidone was 4.0% (1/25) vs. 25.7% (9/35) for those switched from risperidone to olanzapine. High doses yielded a 15.5% response (14.6% for risperidone vs. 16.7% for olanzapine).The present findings concur with other research indicating that response rate to the initial antipsychotic trial in first-episode schizophrenia is robust; thereafter it declines notably. In general, the proportion of responders to antipsychotic switching and high dose interventions was low. For both strategies olanzapine proved superior to risperidone, particularly in the case of antipsychotic switching (i.e. risperidone to olanzapine vs. vice versa). It remains to be established whether further antipsychotic trials are associated with even greater decrements in rate of response. Findings underscore the importance of moving to clozapine when treatment resistance has been established.
机译:治疗精神分裂症的临床医生通常采用大剂量和/或抗精神病药物转换以达到缓解效果。然而,实际上对于这些方法在早期精神分裂症中的价值知之甚少。数据是从对首发精神分裂症患者实施的治疗算法中收集的,该算法在氯氮平之前以增加的剂量进行了两次抗精神病药物试验。患者最初在三个剂量范围(低,全,高)中使用奥氮平或利培酮治疗,如果反应欠佳,则改用其他抗精神病药。我们对(a)高剂量治疗和(b)抗精神病药转换的价值感兴趣。总共评估了244例患者,对试验1有74.5%(184/244)的响应,对试验2仅有16.7%(10/60)的响应。从奥氮平转换为利培酮的受试者的响应百分比为4.0%(1 / 25),而将利培酮改为奥氮平的比例为25.7%(9/35)。高剂量可产生15.5%的反应(利培酮为14.6%,奥氮平为16.7%)。本研究结果与其他研究一致,表明对首发精神分裂症的最初抗精神病药物试验的反应率很高。此后它显着下降。通常,抗精神病药物转换和高剂量干预措施的应答者比例很低。对于这两种策略,奥氮平均被证明优于利培酮,特别是在抗精神病药物转换的情况下(即利培酮改为奥氮平,反之亦然)。进一步的抗精神病药物试验是否与更大的缓解率相关联还有待确定。这些发现强调了已建立治疗耐药性的氯氮平的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号